Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INCR NASDAQ:MRKR NASDAQ:PMVP NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINCRInterCure$1.52+1.3%$1.52$1.17▼$2.62$68.36M1.1825,869 shs22,951 shsMRKRMarker Therapeutics$1.70-11.5%$1.46$0.95▼$5.95$21.72M1.43342,236 shs1.77 million shsPMVPPMV Pharmaceuticals$1.33$1.06$0.81▼$1.82$69.10M1.49198,171 shs172,565 shsVNRXVolitionRx$0.68-0.2%$0.63$0.40▼$0.94$70.19M1.2207,835 shs158,216 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINCRInterCure+1.33%-2.25%+2.36%+10.55%-36.93%MRKRMarker Therapeutics-11.46%-0.58%+15.65%+47.83%-71.48%PMVPPMV Pharmaceuticals0.00%+5.56%+20.91%+30.39%-17.39%VNRXVolitionRx-0.19%+1.09%+0.57%+37.76%+3.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINCRInterCure0.5695 of 5 stars0.03.00.00.02.80.00.6MRKRMarker Therapeutics4.2945 of 5 stars3.85.00.03.92.50.80.0PMVPPMV Pharmaceuticals3.196 of 5 stars3.53.00.00.03.32.50.6VNRXVolitionRx2.1395 of 5 stars3.50.00.00.02.22.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINCRInterCure 0.00N/AN/AN/AMRKRMarker Therapeutics 3.50Strong Buy$13.17674.51% UpsidePMVPPMV Pharmaceuticals 3.00Buy$5.50313.53% UpsideVNRXVolitionRx 3.00Buy$3.50418.52% UpsideCurrent Analyst Ratings BreakdownLatest MRKR, VNRX, INCR, and PMVP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.007/9/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.006/10/2025VNRXVolitionRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$3.004/30/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINCRInterCure$64.55MN/AN/AN/A$2.36 per shareN/AMRKRMarker Therapeutics$6.59M2.92N/AN/A$1.73 per share0.98PMVPPMV PharmaceuticalsN/AN/AN/AN/A$3.40 per shareN/AVNRXVolitionRx$1.31M53.65N/AN/A($0.11) per share-6.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINCRInterCure-$18.32MN/A0.00∞N/AN/AN/AN/A8/28/2025 (Estimated)MRKRMarker Therapeutics-$10.73M-$1.33N/AN/AN/A-224.46%-101.87%-83.02%8/13/2025 (Estimated)PMVPPMV Pharmaceuticals-$58.71M-$1.18N/AN/AN/AN/A-32.54%-29.59%8/6/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.27N/A∞N/A-2,321.14%N/A-163.39%N/ALatest MRKR, VNRX, INCR, and PMVP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025PMVPPMV Pharmaceuticals-$0.39N/AN/AN/AN/AN/A8/13/2025Q2 2025MRKRMarker Therapeutics-$0.55N/AN/AN/A$0.72 millionN/A5/9/2025Q1 2025PMVPPMV Pharmaceuticals-$0.37-$0.34+$0.03-$0.34N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINCRInterCureN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/APMVPPMV PharmaceuticalsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINCRInterCure0.341.731.18MRKRMarker TherapeuticsN/A6.796.79PMVPPMV PharmaceuticalsN/A16.7516.75VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINCRInterCure8.34%MRKRMarker Therapeutics22.39%PMVPPMV Pharmaceuticals90.20%VNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipINCRInterCure0.24%MRKRMarker Therapeutics14.50%PMVPPMV Pharmaceuticals7.57%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINCRInterCure350N/AN/AOptionableMRKRMarker Therapeutics6011.31 million9.67 millionNot OptionablePMVPPMV Pharmaceuticals5051.95 million48.02 millionOptionableVNRXVolitionRx80103.98 million80.80 millionOptionableMRKR, VNRX, INCR, and PMVP HeadlinesRecent News About These CompaniesVolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral CapitalJuly 17 at 9:07 AM | marketbeat.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16 at 8:00 AM | prnewswire.comVolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral CapitalJuly 12, 2025 | americanbankingnews.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comVolition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ FailureJune 12, 2025 | prnewswire.comJones Trading Initiates Coverage of VolitionRx (VNRX) with Buy RecommendationJune 11, 2025 | msn.comVolitionRx director Guy Innes buys $10,772 in common stockJune 5, 2025 | investing.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of StockJune 5, 2025 | insidertrades.comVolition Announces Two Oral Presentations at Asian Meeting of Animal Medicine SpecialtiesJune 4, 2025 | prnewswire.comVolitionRX shares hold as Benchmark maintains ratingMay 21, 2025 | uk.investing.comVolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comInsider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of StockMay 20, 2025 | insidertrades.comVolitionRx Limited Announces Successful Detection of Nucleosomes in CatsMay 19, 2025 | prnewswire.comVolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advancesMay 16, 2025 | msn.comVolitionRX Limited (VNRX) Q1 2025 Earnings Call TranscriptMay 16, 2025 | seekingalpha.comVolitionRx Limited Announces First Quarter 2025 Financial Results and Business UpdateMay 15, 2025 | prnewswire.comVolitionRx Limited Schedules First Quarter 2025 Earnings Conference Call and Business UpdateMay 12, 2025 | prnewswire.comVolitionRX Limited: Outlines broad strategy to become the 'NETs company' worldwide through licensing and updates progress of Nu.Q® NETs test adoptionMay 7, 2025 | prnewswire.comVolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar marketsApril 29, 2025 | prnewswire.comVolitionRx enters new sales agreement, terminates old oneApril 24, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Semiconductor Stocks Poised to Surge on AI SpendingBy Chris Markoch | June 25, 2025View 3 Semiconductor Stocks Poised to Surge on AI SpendingMarvell's New AI Chip Deals Capture Wall Street’s AttentionBy Jeffrey Neal Johnson | June 21, 2025View Marvell's New AI Chip Deals Capture Wall Street’s AttentionBest Prime Day Ever? Here Are the Prime Winners Riding the WaveBy Thomas Hughes | July 14, 2025View Best Prime Day Ever? Here Are the Prime Winners Riding the WaveSalesforce Stock Set for 30% Upside to Reach New HighsBy Thomas Hughes | July 16, 2025View Salesforce Stock Set for 30% Upside to Reach New HighsSpotify's Massive Rally: Can New Features Sustain the Momentum?By Nathan Reiff | June 27, 2025View Spotify's Massive Rally: Can New Features Sustain the Momentum?MRKR, VNRX, INCR, and PMVP Company DescriptionsInterCure NASDAQ:INCR$1.52 +0.02 (+1.33%) Closing price 07/18/2025 03:57 PM EasternExtended Trading$1.46 -0.05 (-3.62%) As of 07/18/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Marker Therapeutics NASDAQ:MRKR$1.70 -0.22 (-11.46%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.70 0.00 (0.00%) As of 07/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.PMV Pharmaceuticals NASDAQ:PMVP$1.33 0.00 (0.00%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.32 -0.02 (-1.13%) As of 07/18/2025 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.VolitionRx NYSE:VNRX$0.68 0.00 (-0.19%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$0.68 +0.00 (+0.44%) As of 07/18/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
